| Item 1. | |
| (a) | Name of issuer:
ProQR Therapeutics N.V. |
| (b) | Address of issuer's principal executive offices:
Zernikedreef 9 Leiden, The Netherlands, CK 2333 |
| Item 2. | |
| (a) | Name of person filing:
(i) Stichting Aescap Life Sciences ("Aescap Life Sciences")
(ii) Privium Fund Management B.V. ("Privium"), as the fund manager of Aescap Life Sciences
(iii) Stichting Aescap Genetics ("Aescap Genetics")
(iv) Inspirational Visions BV ("Inspirational Visions")
(v) Patrick Johan Hendrik Krol ("Krol"), the portfolio manager for Privium regarding Aescap Life Sciences and Aescap Genetics and the managing director of Inspirational Visions
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." |
| (b) | Address or principal business office or, if none, residence:
The principal business address of each of Aescap Life Sciences, Privium, Aescap Genetics and Krol is:
Gustav Mahlerplein 3
1082 MS Amsterdam
The Netherlands
The principal business address of Inspirational Visions is:
A.J. Ernststraat 595-C
1082 LN Amsterdam
The Netherlands |
| (c) | Citizenship:
The citizenship of each of the Reporting Persons is the Netherlands. |
| (d) | Title of class of securities:
Ordinary Shares, nominal value EUR0.04 per share |
| (e) | CUSIP No.:
N71542109 |
| Item 3. | If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| (a) |  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
|
| (b) | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
|
| (c) | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
|
| (d) | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
|
| (e) | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
|
| (f) | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
|
| (g) | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
|
| (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
|
| (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
|
| (j) | A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
|
| (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
|
| | |
| Item 4. | Ownership |
| (a) | Amount beneficially owned:
As its Fund Manager, the Shares held by Aescap Life Sciences may be deemed to be beneficially owned by Privium. In addition, as its Fund Manager, the Shares held by Aescap Genetics may be deemed to be beneficially owned by Privium. As the portfolio manager of Privium, Krol may be deemed to beneficially own the Shares held by Aescap Life Sciences and Aescap Genetics. In addition, as the managing director of Inspirational Visions, Krol may be deemed to beneficially own the Shares held by Inspirational Visions.
As of the date of this report, Aescap Life Sciences directly held 4,156,878 Shares. As of the date of this report, Aescap Genetics directly held 1,310,271 Shares. As of the date of this report, Inspirational Visions directly held 35,411 Shares. As of the date of this report, Krol directly held 26,302 Shares. |
| (b) | Percent of class:
Aescap Life Sciences may be deemed the beneficial owner of approximately 3.9% of the Shares outstanding.
Privium may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding.
Aescap Genetics may be deemed the beneficial owner of approximately 1.2% of the Shares outstanding.
Inspirational Visions may be deemed the beneficial owner of approximately 0.1% of the Shares outstanding.
Krol may be deemed the beneficial owner of approximately 5.2% of the Shares outstanding. |
| (c) | Number of shares as to which the person has:
|
| | (i) Sole power to vote or to direct the vote:
Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862
|
| | (ii) Shared power to vote or to direct the vote:
Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0
|
| | (iii) Sole power to dispose or to direct the disposition of:
Aescap Life Sciences: 4,156,878
Privium: 5,467,149
Aescap Genetics: 1,310,271
Inspirational Visions: 35,411
Krol: 5,528,862
|
| | (iv) Shared power to dispose or to direct the disposition of:
Aescap Life Sciences: 0
Privium: 0
Aescap Genetics: 0
Inspirational Visions: 0
Krol: 0
|
| Item 5. | Ownership of 5 Percent or Less of a Class. |
| |
Not Applicable
|
| Item 6. | Ownership of more than 5 Percent on Behalf of Another Person. |
| |
Not Applicable
|
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
| |
Not Applicable
|
| Item 8. | Identification and Classification of Members of the Group. |
| |
Not Applicable
|
| Item 9. | Notice of Dissolution of Group. |
| |
Not Applicable
|
Rule 13d-1(c)